OCLGOncologix Tech, Inc.

About Oncologix Tech, Inc. (OCLG)

Oncologix Tech, Inc. (OCLG) is a Shell Companies company headquartered in Los Angeles, CA, United States whose shares trade over-the-counter on the Expert Market tier.

Oncologix Tech, Inc is a biopharmaceutical company whose main products include DNAGO and genomego which provides clinical genetic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases at an affordable price for patients in need with DNAGO AI System and Rare Diseases Genetic Test diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, etc. One test to cover all genes Decoding all genes A genetic variant in a gene causes a rare genetic disease. All DNA sequences of 20,000 genes can be decoded by whole-exome sequencing to maximize the diagnostic yield. With the advanced sequencing technology, 99.3% of gene regions are decoded on average. GenomeGO is working to address the unmet therapeutic challenges in gene editing. Our approach is based on the core principles of innovating and developing the next level of safe and effective treatments for patients with genetic diseases. GenomeGO's proprietary platform technologies in repair template design and optimization provide an opportunity to collaborate with partners who specialize in the development and commercialization of gene editing therapeutics. These products are still at developmental stages and will require substantial capital investment to bring to market.

Products and services

Oncologix Tech, Inc.'s main products include DNAGO and genomego which provides clinical genetic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases at an affordable price for patients in need with DNAGO AI System and Rare Diseases Genetic Test diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, etc. One test to cover all genes Decoding all genes A genetic variant in a gene causes a rare genetic disease. All DNA sequences of 20,000 genes can be decoded by whole-exome sequencing to maximize the diagnostic yield. With the advanced sequencing technology, 99.3% of gene regions are decoded on average.

OCLG key facts

Ticker symbol

OCLG

Market tier

Expert Market

Sector

Financial Services

Industry

Shell Companies

Headquarters

Los Angeles, CA, United States

Country of incorporation

US

Year of incorporation

1997

Employees

23

Estimated market cap

$166.2K (as of May 8, 2025)

Shares outstanding

1,662,469,227

Reporting standard

Dark: Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

8/31

Latest filing

Quarterly Report (Nov 30, 2022)

Oncologix Tech, Inc. leadership

• Chang Guen Yoo — President, CEO
• Young Ju Kim — CFO, Treasurer
• Frank lkechukwu Igwealor — Consultant, Accountant

Explore more: Shell Companies stocks · Financial Services sector · Expert Market stocks · OTC stocks starting with O